CEO of Midatech Pharma shares his views on UK life science investment [video]

During the recent HealthEx London forum at One George Street, Westminster, Biotech and Money had the opportunity to interview several CEOs from highly successful, leading biotech and investment firms.

In this video we talk to Dr Jim Phillips, CEO of Midatech Pharma. A physician by training, Jim has a strong and hugely varied background in corporate leadership and strategy. As well as leading Midatech, Jim is currently a non-executive director of Helsinki-listed Herantis Pharma plc and Insense ltd – a Unilever private spin-out. He has also previously served as chairman of Prosonix Ltd.

In 2004, Jim founded Talisker Pharma, the first cornerstone acquisition of EUSA Pharma Inc, for which Jim has previously served as Senior Vice President of Corporate Development. During his time at EUSA Pharma, Jim acquired OPI for the company and led strategy for its eventual acquisition by Jazz Pharmaceuticals.

Jim has also held senior executive positions for Johnson & Johnson and Novartis Pharmaceuticals – where he worked in clinical development and leadership and was a board director for its $1.3 billion Arthritis, Bone, Gastrointestinal, Haematology and Infectious Diseases business unit.

In this interview, we ask Jim for his thoughts on the future of the UK life sciences industry, the biggest opportunities for investment in the foreseeable future and the major challenges that are faced by UK life sciences CEOs.

Click the image to view the short video.

Other videos in this series includes short interviews with Gil Bar-Nahum, Managing Director, Global Healthcare Investment Banking, Jefferies & Co., Justin Gover, CEO, GW Pharmaceuticals, Neil Murray, CEO, Redx Pharma and Wolfgang Rencken, CEO, Sphere Medical.

To enquire about involvement in our 2016 HealthEx London forum, taking place during Biotech and Money London 2016 on 2-3 February as a Partner click here. If you are interested in being selected as a delegate click here.

Tags :

Leave a comment